Hexylresorcinol | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | |
Hexylresorcinol | hsa00220 | Arginine biosynthesis | 1.58E-02 | 2 | P05089, P49448 | ARG1, GLUD2 | More | |
Hexylresorcinol | hsa00340 | Histidine metabolism | 4.52E-02 | 1 | O95954 | FTCD | More | |
Hexylresorcinol | hsa00512 | Mucin type O-glycan biosynthesis | 3.78E-02 | 2 | O95395, Q8N4A0 | GCNT3, GALNT4 | More | |
Hexylresorcinol | hsa00564 | Glycerophospholipid metabolism | 9.70E-03 | 2 | Q9Y259, P49619 | CHKB, DGKG | More | |
Hexylresorcinol | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | |
Hexylresorcinol | hsa00830 | Retinol metabolism | 1.13E-02 | 3 | P11766, P00352, Q9BPW9 | ADH5, ALDH1A1, DHRS9 | More | |
Hexylresorcinol | hsa00920 | Sulfur metabolism | 3.18E-02 | 1 | Q16762 | TST | More | |
Hexylresorcinol | hsa00970 | Aminoacyl-tRNA biosynthesis | 3.78E-02 | 2 | O95363, Q15046 | FARS2, KARS | More | |
Hexylresorcinol | hsa01100 | Metabolic pathways | 2.25E-02 | 7 | Q9Y259, Q13956, P49619, O95954, Q02318, Q9UBX8, P35573 | CHKB, PDE6H, DGKG, FTCD, CYP27A1, B4GALT6, AGL | More | |
Hexylresorcinol | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.82E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa01522 | Endocrine resistance | 2.16E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa02010 | ABC transporters | 4.93E-02 | 1 | Q8IZY2 | ABCA7 | More | |
Hexylresorcinol | hsa03040 | Spliceosome | 1.28E-05 | 13 | O43143, O60508, P08579, P26368, Q13595, Q07955, Q01130, P84103, Q13243, P11142, Q9Y2W2, O43447, O75643 | DHX15, CDC40, SNRPB2, U2AF2, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, HSPA8, WBP11, PPIH, ASCC3L1 | More | |
Hexylresorcinol | hsa03320 | PPAR signaling pathway | 1.62E-02 | 2 | Q13133, Q02318 | NR1H3, CYP27A1 | More | |
Hexylresorcinol | hsa04010 | MAPK signaling pathway | 4.15E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04012 | ErbB signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04014 | Ras signaling pathway | 1.13E-02 | 9 | P04049, P42338, P20827, P49767, Q13009, Q7LDG7, P63218, P50151, P19174 | RAF1, PIK3CB, EFNA1, VEGFC, TIAM1, RASGRP2, GNG5, GNG10, PLCG1 | More | |
Hexylresorcinol | hsa04015 | Rap1 signaling pathway | 8.30E-04 | 12 | P04049, P20827, P49767, Q96FS4, P11215, P25116, Q8TEU7, Q13009, Q7LDG7, P42338, P08514, P19174 | RAF1, EFNA1, VEGFC, SIPA1, ITGAM, F2R, RAPGEF6, TIAM1, RASGRP2, PIK3CB, ITGA2B, PLCG1 | More | |
Hexylresorcinol | hsa04022 | cGMP-PKG signaling pathway | 3.15E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04024 | cAMP signaling pathway | 2.49E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04062 | Chemokine signaling pathway | 3.64E-03 | 11 | P09769, P07948, P42338, P19174, P63218, P50151, P43250, Q7LDG7, Q13009, P04049, Q8WYR1 | FGR, LYN, PIK3CB, PLCG1, GNG5, GNG10, GRK6, RASGRP2, TIAM1, RAF1, PIK3R5 | More | |
Hexylresorcinol | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04071 | Sphingolipid signaling pathway | 2.16E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04072 | Phospholipase D signaling pathway | 2.82E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04110 | Cell cycle | 3.57E-02 | 3 | Q9UBD5, P06493, P33981 | ORC3, CDK1, TTK | More | |
Hexylresorcinol | hsa04122 | Sulfur relay system | 3.18E-02 | 1 | Q16762 | TST | More | |
Hexylresorcinol | hsa04140 | Autophagy - animal | 2.82E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04150 | mTOR signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04151 | PI3K-Akt signaling pathway | 3.70E-02 | 12 | P42338, P43657, P20827, P49767, P08238, Q8WYR1, P63218, P50151, O15335, Q13751, P14784, P30281 | PIK3CB, P2RY5, EFNA1, VEGFC, HSP90AB1, PIK3R5, GNG5, GNG10, CHAD, LAMB3, IL2RB, CCND3 | More | |
Hexylresorcinol | hsa04210 | Apoptosis | 2.16E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04218 | Cellular senescence | 2.49E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04270 | Vascular smooth muscle contraction | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04360 | Axon guidance | 1.51E-02 | 7 | P16333, P20827, O95631, P42338, P07332, P04049, P19174 | NCK1, EFNA1, NTN1, PIK3CB, FES, RAF1, PLCG1 | More | |
Hexylresorcinol | hsa04370 | VEGF signaling pathway | 8.29E-03 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04371 | Apelin signaling pathway | 4.16E-03 | 8 | P63218, P50151, Q8WYR1, P04049, Q14814, Q14344, Q13485, P84022 | GNG5, GNG10, PIK3R5, RAF1, MEF2D, GNA13, SMAD4, SMAD3 | More | |
Hexylresorcinol | hsa04510 | Focal adhesion | 3.48E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04512 | ECM-receptor interaction | 3.73E-02 | 2 | P07359, P08514 | GP1BA, ITGA2B | More | |
Hexylresorcinol | hsa04514 | Cell adhesion molecules | 8.19E-03 | 3 | P16109, P56750, O00501 | SELP, CLDN17, CLDN5 | More | |
Hexylresorcinol | hsa04530 | Tight junction | 1.38E-04 | 5 | Q8TEU7, P16989, P56750, O00501, Q14247 | RAPGEF6, CSDA, CLDN17, CLDN5, CTTN | More | |
Hexylresorcinol | hsa04540 | Gap junction | 1.33E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.99E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04610 | Complement and coagulation cascades | 1.03E-03 | 3 | P25116, P09871, P0C0L4 | F2R, C1S, C4A | More | |
Hexylresorcinol | hsa04611 | Platelet activation | 5.18E-05 | 5 | P25116, P08514, Q15746, Q8WYR1, P07359 | F2R, ITGA2B, MYLK, PIK3R5, GP1BA | More | |
Hexylresorcinol | hsa04613 | Neutrophil extracellular trap formation | 2.81E-03 | 5 | P04049, P16109, O60814, P08514, P07359 | RAF1, SELP, H2BC12, ITGA2B, GP1BA | More | |
Hexylresorcinol | hsa04625 | C-type lectin receptor signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04630 | JAK-STAT signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04650 | Natural killer cell mediated cytotoxicity | 1.82E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04658 | Th1 and Th2 cell differentiation | 3.24E-02 | 4 | P09693, Q16539, P01730, P23771 | CD3G, MAPK14, CD4, GATA3 | More | |
Hexylresorcinol | hsa04659 | Th17 cell differentiation | 1.70E-02 | 7 | P19174, P14784, P14778, P84022, Q13485, P08238, P07766 | PLCG1, IL2RB, IL1R1, SMAD3, SMAD4, HSP90AB1, CD3E | More | |
Hexylresorcinol | hsa04660 | T cell receptor signaling pathway | 1.66E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04662 | B cell receptor signaling pathway | 2.42E-03 | 6 | P42338, P60033, P07948, P21854, Q8N149, P04049 | PIK3CB, CD81, LYN, CD72, LILRA2, RAF1 | More | |
Hexylresorcinol | hsa04664 | Fc epsilon RI signaling pathway | 5.86E-03 | 5 | P42338, P07948, P19174, P04049, P09917 | PIK3CB, LYN, PLCG1, RAF1, ALOX5 | More | |
Hexylresorcinol | hsa04666 | Fc gamma R-mediated phagocytosis | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04720 | Long-term potentiation | 1.66E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04722 | Neurotrophin signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04726 | Serotonergic synapse | 1.33E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04730 | Long-term depression | 1.16E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04810 | Regulation of actin cytoskeleton | 7.86E-03 | 4 | Q15746, P04049, P08514, P25116 | MYLK, RAF1, ITGA2B, F2R | More | |
Hexylresorcinol | hsa04910 | Insulin signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04912 | GnRH signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04914 | Progesterone-mediated oocyte maturation | 2.16E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04915 | Estrogen signaling pathway | 2.99E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04916 | Melanogenesis | 1.33E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04917 | Prolactin signaling pathway | 6.63E-03 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04919 | Thyroid hormone signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04921 | Oxytocin signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04926 | Relaxin signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04928 | Parathyroid hormone synthesis, secretion and action | 1.99E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04929 | GnRH secretion | 4.98E-03 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 3.21E-02 | 5 | P84022, Q13485, P42338, P49767, P19174 | SMAD3, SMAD4, PIK3CB, VEGFC, PLCG1 | More | |
Hexylresorcinol | hsa04935 | Growth hormone synthesis, secretion and action | 2.16E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | |
Hexylresorcinol | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | |
Hexylresorcinol | hsa05034 | Alcoholism | 2.49E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.29E-02 | 3 | Q16539, P09341, P25024 | MAPK14, CXCL1, CXCR1 | More | |
Hexylresorcinol | hsa05130 | Pathogenic Escherichia coli infection | 7.39E-03 | 4 | Q14247, P56750, O00501, P25116 | CTTN, CLDN17, CLDN5, F2R | More | |
Hexylresorcinol | hsa05132 | Salmonella infection | 4.98E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa05133 | Pertussis | 1.86E-03 | 3 | P09871, P0C0L4, Q02556 | C1S, C4A, IRF8 | More | |
Hexylresorcinol | hsa05143 | African trypanosomiasis | 1.31E-02 | 2 | P69905, P68871 | HBA2, HBB | More | |
Hexylresorcinol | hsa05144 | Malaria | 3.09E-02 | 2 | P69905, P68871 | HBA2, HBB | More | |
Hexylresorcinol | hsa05152 | Tuberculosis | 3.98E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa05160 | Hepatitis C | 1.99E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa05161 | Hepatitis B | 1.99E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa05163 | Human cytomegalovirus infection | 4.98E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa05164 | Influenza A | 3.65E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 3.15E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa05170 | Human immunodeficiency virus 1 infection | 3.48E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa05200 | Pathways in cancer | 9.46E-03 | 17 | Q13751, P42338, P08238, P19174, P43246, P84022, Q13485, Q13547, P30281, P49767, P43657, P63218, P50151, Q14344, Q7LDG7, O75293, P14784 | LAMB3, PIK3CB, HSP90AB1, PLCG1, MSH2, SMAD3, SMAD4, HDAC1, CCND3, VEGFC, P2RY5, GNG5, GNG10, GNA13, RASGRP2, GADD45B, IL2RB | More | |
Hexylresorcinol | hsa05205 | Proteoglycans in cancer | 3.48E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa05206 | MicroRNAs in cancer | 3.15E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa05210 | Colorectal cancer | 1.66E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa05211 | Renal cell carcinoma | 1.16E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa05212 | Pancreatic cancer | 8.83E-03 | 5 | P42338, P04049, P84022, Q13485, O75293 | PIK3CB, RAF1, SMAD3, SMAD4, GADD45B | More | |
Hexylresorcinol | hsa05213 | Endometrial cancer | 9.95E-03 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa05214 | Glioma | 9.95E-03 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa05215 | Prostate cancer | 1.33E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa05218 | Melanoma | 6.63E-03 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa05219 | Bladder cancer | 4.98E-03 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa05220 | Chronic myeloid leukemia | 3.00E-03 | 6 | Q13547, Q13485, P84022, P42338, P04049, O75293 | HDAC1, SMAD4, SMAD3, PIK3CB, RAF1, GADD45B | More | |
Hexylresorcinol | hsa05221 | Acute myeloid leukemia | 8.29E-03 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa05223 | Non-small cell lung cancer | 6.63E-03 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa05224 | Breast cancer | 1.49E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa05225 | Hepatocellular carcinoma | 1.33E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa05226 | Gastric cancer | 8.29E-03 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa05230 | Central carbon metabolism in cancer | 9.95E-03 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa05231 | Choline metabolism in cancer | 1.55E-03 | 3 | P04049, Q9Y259, P49619 | RAF1, CHKB, DGKG | More | |
Hexylresorcinol | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.66E-02 | 1 | P04049 | RAF1 | More | |
Hexylresorcinol | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | |
Resorcinol | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | |
Resorcinol | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | |
Resorcinol | hsa00983 | Drug metabolism - other enzymes | 3.50E-02 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | |
Resorcinol | hsa02010 | ABC transporters | 4.93E-02 | 1 | Q8IZY2 | ABCA7 | More | |
Resorcinol | hsa03013 | RNA transport | 3.98E-02 | 9 | P52298, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, P78345, Q9Y6A5 | NCBP2, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, RPP38, TACC3 | More | |
Resorcinol | hsa04064 | NF-kappa B signaling pathway | 1.60E-02 | 8 | P10415, O00463, Q04759, Q9UDY8, Q16548, Q13315, P24522, P09341 | BCL2, TRAF5, PRKCQ, MALT1, BCL2A1, ATM, GADD45A, CXCL1 | More | |
Resorcinol | hsa04071 | Sphingolipid signaling pathway | 1.48E-03 | 7 | P21453, Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415 | S1PR1, EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2 | More | |
Resorcinol | hsa04080 | Neuroactive ligand-receptor interaction | 3.22E-02 | 7 | P08311, Q15722, P21453, Q9H228, O00398, P21730, Q16581 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, C5AR1, C3AR1 | More | |
Resorcinol | hsa04115 | p53 signaling pathway | 3.98E-02 | 5 | P24522, Q13315, Q53FA7, O95067, P10415 | GADD45A, ATM, TP53I3, CCNB2, BCL2 | More | |
Resorcinol | hsa04146 | Peroxisome | 2.42E-02 | 5 | O43933, P56589, Q9UKG9, O75521, P33121 | PEX1, PEX3, CROT, ECI2, ACSL1 | More | |
Resorcinol | hsa04210 | Apoptosis | 3.77E-02 | 8 | Q13315, P10415, O76075, P24522, Q16548, P43234, P18848, Q14643 | ATM, BCL2, DFFB, GADD45A, BCL2A1, CTSO, ATF4, ITPR1 | More | |
Resorcinol | hsa04610 | Complement and coagulation cascades | 2.33E-03 | 1 | P0C0L4 | C4A | More | |
Resorcinol | hsa04612 | Antigen processing and presentation | 3.21E-02 | 6 | P13765, P48382, P26715, P26717, Q13241, P01732 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, CD8A | More | |
Resorcinol | hsa04613 | Neutrophil extracellular trap formation | 7.32E-03 | 13 | O60603, P05164, P08246, Q9UM07, Q6FI13, Q15080, P20160, P08311, O75015, P21730, P21462, O43315, Q16539 | TLR2, MPO, ELA2, PADI4, H2AC18; H2AC19, NCF4, AZU1, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | |
Resorcinol | hsa04657 | IL-17 signaling pathway | 4.98E-02 | 6 | O00463, Q16539, P14780, Q9UJX4, P80188, P01375 | TRAF5, MAPK14, MMP9, ANAPC5, LCN2, TNF | More | |
Resorcinol | hsa04725 | Cholinergic synapse | 4.83E-02 | 4 | P22694, Q14643, P18848, P10415 | PRKACB, ITPR1, ATF4, BCL2 | More | |
Resorcinol | hsa04915 | Estrogen signaling pathway | 2.96E-02 | 5 | P14780, P22694, P18848, Q14643, P10415 | MMP9, PRKACB, ATF4, ITPR1, BCL2 | More | |
Resorcinol | hsa04918 | Thyroid hormone synthesis | 3.50E-02 | 3 | P22694, P18848, Q14643 | PRKACB, ATF4, ITPR1 | More | |
Resorcinol | hsa04927 | Cortisol synthesis and secretion | 8.60E-03 | 3 | Q14643, P18848, P22694 | ITPR1, ATF4, PRKACB | More | |
Resorcinol | hsa04928 | Parathyroid hormone synthesis, secretion and action | 2.13E-02 | 5 | Q14643, P22694, P23771, P18848, P10415 | ITPR1, PRKACB, GATA3, ATF4, BCL2 | More | |
Resorcinol | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | |
Resorcinol | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | |
Resorcinol | hsa05133 | Pertussis | 4.20E-02 | 1 | P0C0L4 | C4A | More | |
Resorcinol | hsa05143 | African trypanosomiasis | 1.31E-02 | 2 | P69905, P68871 | HBA2, HBB | More | |
Resorcinol | hsa05144 | Malaria | 3.09E-02 | 2 | P69905, P68871 | HBA2, HBB | More | |
Resorcinol | hsa05202 | Transcriptional misregulation in cancer | 8.57E-04 | 16 | Q15532, Q13315, P41732, P14780, P27930, P14923, Q15744, Q16548, Q13077, O15550, P35226, P05164, P12838, P08246, Q9C0K0, P24522 | SS18, ATM, TSPAN7, MMP9, IL1R2, JUP, CEBPE, BCL2A1, TRAF1, UTX, BMI1, MPO, DEFA4, ELA2, BCL11B, GADD45A | More | |
Resorcinol | hsa05321 | Inflammatory bowel disease | 2.29E-02 | 4 | P13765, Q14765, P23771, Q9HBE5 | HLA-DOB, STAT4, GATA3, IL21R | More | |
Resorcinol | hsa05332 | Graft-versus-host disease | 7.89E-03 | 4 | P13765, P10747, P26715, Q13241 | HLA-DOB, CD28, KLRC1, KLRD1 | More | |
Resorcinol | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | |